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pinal muscular atrophy (SMA) is an autosomal recessive
disorder characterized by a loss of 
 
 
 
 motoneurons in
the spinal cord. SMA is caused by low levels of the
ubiquitously expressed survival motor neuron (Smn) protein.
As it is unclear how low levels of Smn speciﬁcally affect
motoneurons, we have modeled SMA in zebraﬁsh, a verte-
brate model organism with well-characterized motoneuron
development. Using antisense morpholinos to reduce Smn
S
 
levels throughout the entire embryo, we found motor
axon–speciﬁc pathﬁnding defects. Reduction of Smn in
individual motoneurons revealed that 
 
smn
 
 is acting cell
autonomously. These results show for the ﬁrst time, in
vivo, that Smn functions in motor axon development and
suggest that these early developmental defects may lead to
subsequent motoneuron loss.
 
Introduction
 
Zebrafish is an excellent organism for studying human dis-
ease (Dodd et al., 2000) due to its well-characterized embry-
onic development and the ability to perform both forward
and reverse genetics (for review see Grunwald and Eisen,
2002). Protein knockdown technology has facilitated analysis
of zebrafish forms of muscular dystrophy (Parsons et al.,
2002) and cystic kidney disease (Liu et al., 2002). Due to its
well-characterized nervous system and relatively simple neuro-
muscular organization, zebrafish are well suited for analysis
of neuromuscular diseases. Taking advantage of these attributes,
we have used protein knockdown in zebrafish to model
spinal muscular atrophy (SMA).
SMA, an autosomal recessive disorder, is the leading
hereditary cause of infant mortality (Roberts et al., 1970)
and is characterized by loss of 
 
 
 
 motoneurons in the spinal
cord (Crawford and Pardo, 1996; Melki, 1997). The disease
results from low levels of the protein encoded by the survival
motor neuron (
 
SMN
 
) gene. Although SMN is expressed in
all cell types, motoneurons are specifically affected in SMA,
indicating their sensitivity to low SMN levels (Coovert et al.,
1997; Lefebvre et al., 1997; Monani et al., 2000). Humans
have two copies of the 
 
SMN
 
 gene, 
 
SMN1
 
 and 
 
SMN2
 
, which
differ in a single base change in a splice enhancer site for
exon 7 of 
 
SMN2
 
 (Lorson et al., 1999; Monani et al., 1999;
Cartegni and Krainer, 2002). Thus, 
 
SMN1
 
 produces a
majority of full-length transcript, whereas 
 
SMN2
 
 generates
mostly transcripts lacking exon 7, although some full-length
transcript is produced (Lefebvre et al., 1995). SMN protein
lacking exon 7 does not oligomerize effectively (Lorson and
Androphy, 1998) and appears to be unstable and rapidly
degraded (Lorson and Androphy, 2000). Thus, mutations in
 
SMN1,
 
 but retention of the 
 
SMN2
 
 gene, results in reduced
protein levels and ultimately SMA (Lefebvre et al., 1995,
1997; Coovert et al., 1997).
The 38-kD SMN protein is ubiquitously expressed and
localizes to both the cytoplasm and nucleus (Liu and Dreyfuss,
1996; Coovert et al., 1997; Lefebvre et al., 1997). In the
nucleus, SMN localizes to structures termed gems, which
overlap or are in close proximity to coiled bodies (Liu and
Dreyfuss, 1996; Young et al., 2000a). It has been termed the
master RNA assembler and, in particular, has been shown to
be important in assembly of snRNP particles (for review see
Terns and Terns, 2001). SMN also binds to the hn-RNP-R,
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which is involved in RNA editing and mRNA transport
(Rossoll et al., 2002). Recent data shows that hn-RNP-R
colocalizes with SMN in distal axons of embryonic moto-
neurons (Jablonka et al., 2001; Rossoll et al., 2002). SMN
also has been shown to localize in the growth cones and
branch points of developing neurons (Jablonka et al., 2001;
Fan and Simard, 2002; Zhang et al., 2003). Ultimately,
however, the function of SMN in relation to SMA pathol-
ogy and etiology remains unclear.
To further analyze SMN function, animal models of SMA
have been generated (Schrank et al., 1997; Hsieh-Li et al.,
2000; Monani et al., 2000; Cifuentes-Diaz et al., 2002; Mo-
nani et al., 2003). In contrast to humans, mice have only
one 
 
Smn
 
 gene, which is equivalent to human 
 
SMN1
 
 (DiDo-
nato et al., 1997; Viollet et al., 1997). Complete loss of this
gene results in an embryonic lethal phenotype (Schrank et
al., 1997). Introduction of one or two copies of human
 
SMN2
 
 rescues the embryonic lethal phenotype and results in
mice with severe SMA (Hsieh-Li et al., 2000; Monani et al.,
2000), whereas 8–16 copies of 
 
SMN2
 
 completely rescue the
SMA phenotype (Monani et al., 2000). Although both se-
vere and mild SMA mice ultimately exhibit motoneuron cell
body reduction (Monani et al., 2000, 2003), no early mor-
phological or biochemical abnormality of the motoneurons
has been reported.
A model of SMA in zebrafish has the potential to elucidate
the effect of decreased Smn levels on motoneuron develop-
ment in vivo. At 24 h, there are three well-characterized pri-
mary motoneurons per spinal cord hemisegment that inner-
vate either the dorsal, rostral, or ventral region of each
myotome (Eisen et al., 1986; for review see Beattie, 2000;
Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200303168/DC1). Over the next few days, each of the
primary motor axons are joined by 20–30 secondary motor
axons, which form three distinct nerves that innervate the
three myotome regions (Myers et al., 1986; Pike et al.,
1992). As these axons extend into defined myotome regions,
they can be followed in living embryos; thus, perturbations
in the organization of these neurons or their axons can be
readily detected, followed during development, and quanti-
tated (for review see Beattie, 2000).
We have used antisense morpholino technology to model
the effects of low levels of 
 
smn
 
 in zebrafish. Reducing Smn
protein levels in the developing embryo results in motor
axon–specific truncations and branches, independent of mo-
toneuron cell death. Moreover, by decreasing Smn levels in
single motoneurons, we show that these defects are due to a
cell-autonomous function of Smn in motoneurons. These
are the first reported morphological abnormalities of moto-
neuron development in response to low levels of Smn. These
data reveal that one of the earliest consequences of Smn pro-
tein reduction is severely compromised motor axon out-
growth, indicative of an essential role for Smn in motoneu-
ron development.
 
Results
 
Mapping and expression of 
 
smn
 
The zebrafish 
 
smn
 
 gene was mapped to linkage group 5 on
the LN 54 radiation hybrid panel (Hukriede et al., 1999).
Southern blot and radiation hybrid mapping (unpublished
data) indicated that there is only a single 
 
smn
 
 gene in
zebrafish. RNA in situ hybridization showed that, like
its mammalian counterpart, zebrafish 
 
smn
 
 appears to be
expressed in all cell types based on diffuse and ubiqui-
tous staining at 22, 27, 36, and 48 h after fertilization (h;
Fig. S2, available at http://www.jcb.org/cgi/content/full/
jcb.200303168/DC1).
 
Knockdown of Smn causes spinal motor axon defects
 
Morpholino antisense oligonucleotide “knockdown” tech-
nology was performed in zebrafish to decrease the levels of
the Smn protein and mimic SMA. Morpholino oligonucle-
otides (MOs) inhibit the translation of their target mRNA,
thereby causing reduced levels of target protein (Nasevicius
and Ekker, 2000). Control or 
 
smn
 
 MO was injected into
embryos at the one- to four-cell stage, and then embryos
were allowed to develop until the desired time. Western blot
analysis showed that 
 
smn
 
 MO–injected embryos exhibited a
61% decrease in Smn protein at 36 h (Fig. 1, A and B). Ap-
proximately 78% (
 
n
 
 
 
  
 
580) of embryos injected with 6 ng
of 
 
smn
 
 MO survived compared with 91% (
 
n
 
 
 
  
 
139) survival
when injected with the same concentration of control MO.
Embryos died between late gastrulation and early somitoge-
nesis, suggesting essential Smn function during zebrafish de-
velopment. 
 
smn
 
 MO–injected embryos that survived did not
exhibit gross abnormalities.
Initial examination focused on a subset of primary moto-
neurons. Cell bodies of caudal primary (CaP) and variable
primary (VaP) motoneurons are located in the middle of
each spinal cord hemisegment and express the LIM gene
 
islet2
 
 (Appel et al., 1995). Using 
 
islet2
 
 RNA in situ hybrid-
ization, we found that these motoneurons were present in
both control MO (
 
n
 
 
 
  
 
6) and 
 
smn
 
 MO–injected embryos
(
 
n
 
 
 
  
 
42; unpublished data). Using the znp1 mAb, we ex-
amined CaP motor axons. At 27 h, CaP axon projections
have a stereotyped morphology and project into ventral
muscle, as shown in a control MO–injected embryo (Fig. 1
C). 
 
smn
 
 MO–injected embryos, however, showed motor
axon defects that could be grouped into two categories
based on axon length and axon branching. Approximately
35.3% of 
 
smn
 
 MO–injected embryo sides had at least one
truncated motor axon that did not fully project into the
ventral muscle (Table I; Fig. 1 D). Affected sides in 
 
smn
 
MO–injected embryos had an average of 1.90 truncated ax-
ons (Table II). Axon branching was also observed in 
 
smn
 
MO–injected embryos. At 27 h, 14.3% of embryo sides
had at least one branched axon (Table I; Fig. 1 E), and each
affected side had an average of 2.31 branches (Table II).
These defects were typically found between hemisegments
5 and 17, corresponding to middle through posterior
trunk. It was rare that axon defects were seen along the
proximal portion of the axon, between the ventral root and
the first intermediate target at the nascent horizontal myo-
septum (Fig. 1, white arrowhead).
By 36 h, secondary motor axons also extend into the ven-
tral muscle and fasciculate to form a nerve (Fig. 1 F). At 36 h
in 
 
smn
 
 MO–injected embryos, 61.5% of the sides had at
least one truncated axon (Table I; Fig. 1 G), compared with
35.3% at 27 h. Affected sides had an average of 2.81 trun-T
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cated nerves, which is consistent with what was observed
at 27 h (Table II). However, at 36 h, there were more
sides with increased numbers of truncated nerves. 44.6% of
the sides in 
 
smn
 
 MO–injected embryos had at least one
branched nerve (Table I; Fig. 1 H) in contrast to only
23.6% at 27 h. The average number of branches per side re-
mained constant at 2.5 (Table II).
 
Further knockdown of Smn protein results in increased 
motor axon branching
 
It has been shown in human patients and mouse models that
the severity of SMA is dependent on the amount of SMN
protein (Monani et al., 2000). To investigate if motor axon
defects would become more severe when Smn protein was
further reduced, 9 ng of MO was injected into embryos.
Figure 1. Motor axons/nerves are abnormal in embryos injected with 6 ng of smn MO. Western blot analysis of WT uninjected (lanes 1 and 3), 
control MO–injected (lane 2), and smn MO–injected (lane 4) embryos at 36 h (Smn is 37–38 kD). Hu-C, a neuronal marker, is shown as a 
loading control. Lateral views (anterior to the left; dorsal to the top) of whole-mount embryos labeled with znp1 mAb at 27 (C–E) and 36 h 
(F–H) in embryos injected with control MO (C and F) or smn MO (D, E, G, and H). Truncated motor axons/nerves (D and G; black arrowheads) 
and branched motor axons/nerves (E and H; black arrows) occur. White arrows demarcate the proximal axon pathway (C and F). Bars: (C–E) 
25  m; (F–H) 30  m.
 
Table I. 
 
Percentage of sides with at least one of the specified motor axon/nerve defects
Truncation Branching
27 h 36 h 27 h 36 h
 
Control MO
6 ng 3.5 
 
 
 
 11.9
 
a
 
0.0 
 
 
 
 0.0 8.3 
 
 
 
 7.3 0.0 
 
 
 
 0.0
 
n
 
 
 
 
 
 28
 
b
 
n
 
 
 
 
 
 24
 
n
 
 
 
 
 
 24
 
n
 
 
 
 
 
 32
9 ng 5.6 
 
 
 
 11.7 0.0 
 
 
 
 0.0 14.3 
 
 
 
 20.9 0.0 
 
 
 
 0.0
 
n
 
 
 
 
 
 18
 
n
 
 
 
 
 
 28
 
n
 
 
 
 
 
 14
 
n
 
 
 
 
 
 28
 
smn
 
 MO
6 ng 35.3 
 
 
 
 7.6
 
d
 
61.5 
 
 
 
 8.4
 
e
 
23.6 
 
 
 
 7.3
 
c
 
44.6 
 
 
 
 13.4
 
e
 
n
 
 
 
 
 
 156
 
n
 
 
 
 
 
 130
 
n
 
 
 
 
 
 140
 
n
 
 
 
 
 
 130
9 ng 13.6 
 
 
 
 15.6 46.9 
 
 
 
 12.4
 
e
 
77.3 
 
 
 
 17.5
 
e
 
76.6 
 
 
 
 10.5
 
e
 
n
 
 
 
 
 
 81
 
n
 
 
 
 
 
 128
 
n
 
 
 
 
 
 81
 
n
 
 
 
  128
Significance of control MO versus smn MO for each age, defect, and dose was determined by t test.
aPercentage of sides ( 95% confidence interval).
bn, number of embryos.
cP   0.05.
dP   0.0005.
eP   0.0001.T
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Western blot analysis showed a 77% knockdown of protein
(Fig. 2, A and B). In contrast to 89% survival when control
MO was injected (n   164), at this higher dose of smn MO,
only 45% (n   433) of the embryos survived, further sug-
gesting the essentiality of Smn in zebrafish development.
Injecting higher doses of smn MO resulted in a dramatic
increase in motor axon branching. At 27 h, 77.3% of sides
from smn MO embryos had at least one branched motor
axon (Table I; Fig. 2 E). The average number of motor axon
branches per side was also increased at higher doses of MO
(Table II). Branching defects were also significantly in-
creased at 36 h; 76.6% of injected embryo sides had at least
one branched motor nerve, compared with 44.6% of sides
with the lower dose of smn MO (Table I; Fig. 2 H). These
data indicate that the motor axon branching defect is more
severe upon further knockdown of Smn.
Motor axon truncations were less evident at higher smn
MO doses; in fact at 27 h, there is no significant difference
when compared with control MO injections, where 5.6% of
sides had truncated motor axons (Table I, Fig. 2 D). Also, all
of the smn MO defective sides only had one truncated motor
axon (Table II). At 36 h, a similar trend was apparent.
46.9% of 9 ng smn MO–injected embryo sides had at least
one truncated motor nerve, which is slightly reduced com-
pared with lower doses of MO (Table I; Fig. 2 G). The aver-
age number of truncated motor nerves per side is 2.47,
Figure 2. Motor axons/nerves are abnormal in embryos injected with 9 ng of smn MO. Western blot analysis of WT uninjected (lanes 1 and 3), 
control MO–injected (lane 2), and smn MO–injected (9 ng) (lane 4) embryos at 36 h. Hu-C, a neuronal marker, is shown as a loading control. 
Lateral views of whole-mount embryos labeled with znp1 mAb at 27 (C–E) and 36 h (F–H) in embryos injected with control MO (C and F) 
or smn MO (D, E, G, and H). Truncated motor axons/nerves (D and G; black arrowheads) and branched motor axons/nerves (E and H; 
black arrows) occur when Smn protein levels are further reduced. Bars: (C–E) 25  m; (F–H) 30  m.
Table II. Average number of the specified motor axon/nerve defects per affected side
Truncation Branching
27 h 36 h 27 h 36 h
smn MO
6 ng 1.89   0.32
a 2.81   0.60 2.31   0.39 2.50   0.67
n   156
b n   130 n   140 n   130
9 ng 1.00   0.00 2.47   0.57 5.13   2.31
d 5.26   1.41
c
n   81 n   128 n   81 n   128
Significance was determined by a t test comparing each defect at 6 ng to the same defect at 9 ng.
aAt 27 h, 10–12 znp1 mAb–labeled motor axons/nerves were scored per side; at 36 h, 14–16 motor axons/nerves were scored ( 95% confidence interval).
bn, number of embryos.
cP   0.01.
dP   0.0001.T
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slightly less than at lower doses of MO (Table II). These
data suggest that further reduction of Smn protein levels re-
sults in more severe motor nerve branching defects and less
severe truncation defects. To confirm that reduction in Smn
results in motor axon/nerve defects, we used an additional,
nonoverlapping  smn MO and observed similar defects
(Fig.  S3, available at http://www.jcb.org/cgi/content/full/
jcb.200303168/DC1), although this 5  UTR MO was less
efficient than the original MO described (Table SI, available
at http://www.jcb.org/cgi/content/full/jcb.200303168/DC1).
Aberrant motor nerves remain defective over time
To determine the dynamics of the axon defects observed in
smn MO–injected embryos, we analyzed motor nerves over
several days using gata2–GFP transgenic zebrafish (Meng et
al., 1997). In this transgenic line, secondary motoneuron
cell bodies and ventrally projecting axons express GFP start-
ing at  33 h. 9 ng of smn MO or control MO was injected
into gata2–GFP embryos, and ventral motor nerves were vi-
sualized from 36 to 74 h. smn MO was still effective in
knocking down Smn protein at later time points, as evi-
denced by Western blot analysis performed at 74 h, which
shows a 88% reduction in Smn protein (Fig. 3, A and B).
13 individual motor nerves were identified in smn MO–
injected embryos (n   13) at 36 h and were followed until
74 h. At 36 h, each of the 13 nerves was truncated at or near
the ventral edge of the notochord (Fig. 3 D), a second inter-
mediate target for motor axons (Beattie et al., 2000; Fig.
S1). When the same motor nerves were examined at 52 h,
92% (12/13) of the nerves remained truncated but had be-
Figure 3. Time-lapse imaging of defec-
tive motoneurons suggests that truncation 
defects precede branching defects. 
Western blot analysis of WT uninjected 
(lanes 1 and 3), control MO–injected 
(lane 2), and smn MO–injected (9 ng) 
(lane 4) embryos at 74 h. Synaptic vesicle 
protein 2, SV2, is shown as a loading 
control. Lateral views of the medial 
pathway of a GFP-expressing motor 
nerve of a transgenic gata2–GFP embryo 
injected with either control MO (C, E, 
and G; n   10) or smn MO (D, F, and H; 
n   13). Ventral projecting motoneurons 
are shown at 36 (C and D), 50 (E and F), 
and 74 h (G and H). White lines demar-
cate the second intermediate target, the 
ventral aspect of the notochord. Only 
one GFP-expressing motor nerve was 
imaged, compiled, and placed on an 
artificial black background; the additional 
trunk nerves have been removed from 
the image. Bar, 50  m.
Figure 4. Dorsally projecting motor nerves are also truncated and branched when Smn protein is decreased. Lateral view of a confocal image 
of a GFP-expressing, dorsally projecting motor nerves in a transgenic islet1–GFP embryo injected with either 9 ng of control MO (A; n   50) 
or smn MO (B and C; n   89) at 74 h. White arrowhead and asterisk (B) denote a truncated nerve. White arrow (C) indicates a nerve branch 
extending into the adjacent hemisegment. Bar, 50  m.T
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gun to branch (Fig. 3 F). Upon examination at 76 h, 85%
(11/13) of the nerves were truncated and branched (Fig. 3
H). The remaining motor nerves (2/13) that did reach the
ventral muscle projected into the preceding hemisegment,
nearly touching the motor nerve in the adjacent hemiseg-
ment; although these motor nerves were not truncated or
branched, their pathfinding was clearly erroneous. In con-
trast, all of the nerves in control MO–injected embryos (n  
10) exhibited the stereotypic ventral nerve projections (Fig.
3, C, E, and G). These data show that defective motor
nerves are dynamic, first becoming truncated and then
branching at the site of truncation. Thus, nerve truncations
are still occurring at higher doses of smn MO, but the exten-
sive branching obscures this phenotype.
Knockdown of smn also causes aberrant dorsal 
projecting motor nerves
To determine whether other spinal motor axons were af-
fected by decreased levels of Smn protein, we analyzed dorsal
motor nerves in islet1–GFP transgenic zebrafish. Among
other neuronal types, this transgenic line has GFP-express-
ing secondary motoneuron cell bodies and dorsally project-
ing axons (Fig. 4 A; Higashijima et al., 2000). 9 ng of smn
MO or control MO was injected into islet1–GFP transgenic
embryos, and dorsal nerves were analyzed at  74 h. Like
ventral motor nerves, dorsally projecting motor nerves ex-
hibited truncation and branching defects as a result of smn
knockdown (Fig. 4, B and C). Branching is also more prom-
inent at higher doses of smn MO in these nerves. 69.1%
(n   178) of sides of smn MO–injected embryos had at least
one branched dorsal projecting motor nerve, whereas con-
trol MO–injected embryos had only 8.0% of sides with a
branched dorsal nerve (n   50). In contrast, 32.6% (n  
178) of sides of smn MO–injected embryos had at least one
truncated nerve, whereas control MO–injected embryos had
no truncated dorsal projecting nerves (n   50). These de-
fects are consistent with those seen in ventral projecting mo-
tor nerves, suggesting that dorsal projecting motoneurons
are also affected by reduction of Smn protein.
Human SMN mRNA partially rescues motor 
nerve defects
To confirm the specificity of the MO function, RNA
rescue  experiments were performed using human SMN
Figure 5. Decreased levels of Smn do not 
initially result in motoneuron cell death. 
Cross section view (dorsal to the top) of 
TUNEL-stained 50-h control MO–injected 
(A; n   3) and smn MO–injected (9 ng) 
(B; n   15) embryos. TUNEL-positive (purple) 
cells are present on the skin of both the smn 
MO– and control MO–injected embryos, 
which is not uncommon for this assay. 
Occasionally, (B) TUNEL-positive cells 
(black arrowhead) present in the dorsal 
spinal cord, corresponding to the sensory 
Rohon-Beard neurons (entire spinal cord 
demarcated by black dashed lines). Cross 
section view of zn-5 mAb–stained secondary 
motoneuron cell bodies (arrows) of 50-h 
control MO–injected (C; n   6) and smn 
MO–injected (9 ng) (D; n   41) embryos. 
(E) Motor pool diameter ( m) was measured 
on medial-lateral (M-L) and dorsal-ventral 
(D-V) axes (error bars indicate standard error). 
Anterior trunk was defined as hemisegments 
1–5, whereas middle trunk was defined as 
hemisegments 6–14. t test concluded that 
P   0.1 among motor pools of control MO– 
and smn MO–injected embryos. Bar, 25  m.T
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mRNA. One- to four-cell gata2–GFP embryos were in-
jected with a mixture of smn MO (9 ng) and hSMN
mRNA. When compared with smn MO alone, coinjection
of hSMN and smn MO resulted in rescue of both the
branching and truncation nerve defects (Table III). The
partial rescue observed was probably due to the mosaic na-
ture of the mRNA and MO injections, as reported by oth-
ers (McClintock et al., 2002). The specificity of the RNA
rescue was confirmed by the lack of rescue when hSMN 7
mRNA, a common mutation and the major form of
mRNA produced by SMN2, was coinjected with smn MO
(Table III; Lefebvre et al., 1995). The percentage of sides
with branched motor nerves is slightly reduced compared
with MO alone, likely due to the slight activity of the
hSMN 7 protein (Cifuentes-Diaz et al., 2002; unpub-
lished data). These rescue experiments confirm that the
motor nerve defects observed when smn MO is injected are
a result of the reduction of Smn protein and further vali-
date this system as a model for SMA.
Motor axon defects are not caused by cell death
To determine whether the motor axon defects observed
upon smn knockdown were caused by neuronal apoptosis, a
TUNEL assay was performed. Unlike higher vertebrates,
naturally occurring motoneuron cell death in the zebrafish
ventral spinal cord has not been reported (Cole and Ross,
2001). Embryos were injected with 9 ng control MO or
smn MO and then analyzed at 27 (n   10), 36 (n   10),
and 50 h (n   15). None of the injected embryos had any
TUNEL-positive cells in the ventral spinal cord (Fig. 5, A
and B). TUNEL-positive cells could occasionally be seen in
the dorsal spinal cord, corresponding to the Rohon-Beard
sensory neurons (Fig. 5 B; arrowhead), which have previ-
ously been shown to undergo apoptosis at this age (Cole
and Ross, 2001). To further confirm that motoneuron
numbers were not reduced by means other than apoptosis,
the diameter of the spinal motor pool was measured. Em-
bryos injected with control or smn MO were labeled with
anti-neurolin mAb (zn-5), which labels the cell surface of
secondary motoneurons in the spinal cord (Fashena and
Westerfield, 1999). To analyze the motor pool size, the di-
ameter was measured both dorso-ventrally and medio-later-
ally on both sides of the midline (Fig. 5, C and D). There
was no significant difference in motor pool diameter on ei-
ther axis between control MO– and smn MO–injected em-
bryos (Fig. 5 E). These data indicate that the motor axon
defects observed upon Smn reduction are not caused by
motoneuron death and further support the idea that Smn is
needed for motor axon development.
Table III. Percentage of sides with at least one of the specified 
motor nerve defects
Branching Truncation
WT uninjected 19.4   7.6
a 3.7   3.6
n   54
b n   54
smn MO (9 ng) 63.9   6.5 19.4   5.4
n   108 n   108
smn MO (9 ng) and hSMN RNA 37.1   12.4
d 8.1   7.0
c
n   31 n   31
smn MO (9 ng) and hSMN 7 RNA 56.0   8.1 23.3   7.0
n   75 n   75
Significance of hSMN mRNA rescue versus smn MO alone for each defect
was determined by t test.
aGFP-expressing motoneurons were scored at 52 h ( 95% confidence in-
terval).
bn, number of embryos.
cP   0.02.
dP   0.0001.
Figure 6. Other neurons and axon tracts are unaffected upon knockdown of Smn protein. Dorsal view (anterior to the top) of the hindbrain 
stained with acetylated tubulin mAb in 27-h control MO–injected (A; n   40) and smn MO–injected (9 ng) (B; n   39) embryos showing the 
medial longitudinal fascicle (black arrowheads) and the lateral longitudinal fascicle (black arrows). Dorsal view of the hindbrain Mauthner 
neuron cell body and axon (arrowhead) stained with 3A10 mAb in 34-h control MO–injected (C; n   61) and smn MO–injected (D; n   32) 
embryos. Lateral views of (E and F) Rohon-Beard (black arrow) and (G and H) lateral line sensory neurons (white arrow) stained with acetylated 
tubulin mAb in 34-h control MO–injected (E and G; n   40) and smn MO–injected (F and H; n   39) embryos. Bars: (A and B) 50  m; 
(C and D) 40  m; (E–H) 50  m.T
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Other neuronal cell types and axon tracts are not 
affected by Smn knockdown
In human and mouse models of SMA, the affect of de-
creased levels of SMN is specific for motoneurons. To de-
termine if the defects resulting from Smn knockdown were
also motoneuron specific, we examined populations of in-
terneurons and sensory neurons using the acetylated tubu-
lin mAb. Many zebrafish hindbrain interneurons have ste-
reotyped axonal projections that extend into the spinal
cord (Mendelson, 1986; Metcalfe et al., 1986). We saw no
defects in the medial longitudinal fascicle or the lateral lon-
gitudinal fascicle, both of which contain hindbrain and
midbrain axons descending into the spinal cord (Fig. 6, A
and B). To look for more subtle defects, we examined the
single commissural axon of the Mauthner neuron present
in hindbrain rhombomere 4. Using the 3A10 mAb, we
found that in smn MO–injected embryos, the Mauthner
axon projected across the midline and down the spinal
cord in a manner indistinguishable from control MO–
injected embryos (Fig. 6, C and D). Rohon-Beard sensory
neurons, present in the dorsal spinal cord (Lamborghini,
1980; Metcalfe et al., 1990), send axons into the peripheral
muscle and skin. These cells and their axons were also un-
affected by Smn knockdown (Fig. 6, E and F). Lastly, we
looked at the lateral line, a group of sensory neurons that
send axons the length of the developing embryo. We ob-
served no difference in length or morphology of the lateral
line axons in control MO– or smn MO–injected embryos
(Fig. 6, H and G). Thus, interneurons and sensory neurons
are unaffected by decreased levels of Smn protein and sup-
port the finding that motoneurons are uniquely sensitive to
decreased Smn levels.
Smn knockdown does not affect muscle development
To determine whether the motor axon defects observed
were due to defects in muscle development, we examined
the development and patterning of the myotomes. Overall
myotome morphology was analyzed using live gata2–GFP
transgenic embryos injected with either control MO or
smn MO. Nomarski images were taken of muscle segments
containing defective GFP-expressing nerves. No difference
was seen in the muscle morphology between control MO–
and smn MO–injected embryos (Fig. 7, A and B). No de-
fects were seen in early muscle patterning in smn MO–
injected embryos compared with control MO, as assayed
by myoD expression, a gene expressed in the posterior re-
gion of the developing somite (Weinberg et al., 1996; Fig.
7, C and D). Lastly, we asked whether muscle cells were
correctly specified by characterizing slow and fast muscle
in  smn MO–injected embryos. Using the slow muscle
mAb F59 (Crow and Stockdale, 1986; Devoto et al.,
1996) and the fast muscle mAb F310 (Crow and Stock-
dale, 1986; Zeller et al., 2002), we found no difference be-
tween muscle specification and organization upon deple-
tion of Smn (Fig. 7, E–H). These data suggest that low
levels of Smn do not adversely affect muscle organization,
specification, or development.
As motor axons in smn MO embryos displayed aberrant
axon outgrowth, we asked whether these axons were still
capable of forming synapses on the muscle fibers. To ad-
dress this, we analyzed acetylcholine receptor (AChR) clus-
ters in smn MO embryos at 3 d. Using rhodamine-conju-
gated  -bungarotoxin, we found that all axons in smn MO
and control MO embryos colocalized with AChR clusters
(Fig. 8, A–F), suggesting that the axons are innervating
muscle fibers but lack the stereotyped pattern of innerva-
tion (Fig. 8, D–F, arrows). Consistent with this observa-
tion, we found no overt movement defects or paralysis in
these embryos (unpublished data).
Figure 7. Muscle development is normal when Smn is decreased. 
Nomarski lateral views of mid-trunk muscle from 50-h gata2–GFP 
transgenic embryos injected with 9 ng of control MO (A; n   20) 
or smn MO (B; n   20) showing somitic boundaries (black arrows). 
Dorsal views of 22-h whole-mount in situ hybridization of myoD 
(purple; black arrowhead) in control MO–injected (C; n   31) and 
smn MO–injected (D; n   18) embryos. Cross section of 27-h znp1 
(motor axon; arrows) and F59 (slow muscle; arrowheads) mAb–
stained embryos injected with control MO (E; n   40) or smn MO 
(F; n   65). Cross section of 27-h znp1 (motor axon; arrows) and 
F310 (fast muscle; arrowheads) mAb–stained embryos injected with 
control MO (G; n   20) or smn MO (H; n   41). Bars: (A–D) 75  m; 
(E–H) 30  m.T
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Smn is acting cell autonomously in motoneurons
As Smn is expressed in all tissues, it is not clear where its
function is required for normal motor axon development.
To test whether Smn functions cell autonomously with re-
spect to motoneurons, we reduced Smn levels in single mo-
toneurons in otherwise WT embryos. Optical clarity of
zebrafish embryos allows us to identify single primary mo-
toneurons in living embryos and iontophorese these cells
with vital fluorescent dyes (Eisen et al., 1989; Beattie et
al., 2000). smn or control MO was iontophoresed with
rhodamine dextran dye into CaP cell bodies at 19.5–20.5 h;
CaP axons were then imaged at 43 h. 100 and 50  M solu-
tions were found to cause significant cell death when ionto-
phoresed into motoneurons, whereas a solution containing 1
 M of smn MO only caused 45.5% of the CaP motoneu-
rons to die.
CaP motoneurons iontophoresed with 1  M control MO
exhibited no axon defects (n   10; Fig. 9 A). In contrast,
CaP motoneurons, iontophoresed with smn MO when their
growth cones were at the first intermediate target, were de-
fective 76.9% of the time (n   13; Fig. 9, B, C, and D). The
defects observed, axon truncations and branches, were con-
sistent with defects seen when the entire embryo was in-
jected with smn MO. CaP motoneurons were also ionto-
phoresed with smn MO when their growth cones were
further ventral at the second intermediate target. Only
62.5% of these motor axons (n   8; Fig. 9 D) were defec-
tive, suggesting that the longer the Smn protein is reduced
Figure 8. AChR clustering is normal when Smn is decreased. Lateral views of znp1 (A and D; motor axons, green) mAb,  -bungarotoxin 
(B and E; AChR, red) stained, and merge (C and F; yellow) 74-h larvae injected with control MO (A–C; n   18) or smn MO (D–F; n   49). 
Aberrant motor nerve (arrowhead) retains ability to cluster AChR. Bar, 50  m.
Figure 9. Smn is acting cell autono-
mously in CaP motoneurons. Lateral 
views of psuedocolor images of live CaP 
motoneurons directly iontophoresed 
with rhodamine dextran and control MO 
(A; n   10) or smn MO (B and C; n   21) 
visualized and imaged at 43 h. CaP 
motoneurons iontophoresed with smn 
MO exhibit axon branching (B) and 
truncation (C). (D) Percentage of smn 
MO–injected CaP motoneurons with 
defective and normal axons quantitated 
(error bars represent standard error). 
HM, nascent horizontal myoseptum; 
VNC, myotome adjacent to the ventral 
edge of the notochord. Bar, 50  m.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
928 The Journal of Cell Biology | Volume 162, Number 5, 2003
during outgrowth, the more likely pathfinding errors, such
as truncations and branches, will occur. The incomplete
penetrance of these defects may suggest variability in the
phenotype, as is seen when the entire embryo is injected
with smn MO.
To show the specificity of these defects, smn MO and fluo-
rescent rhodamine dextran were also iontophoresed into ven-
tral longitudinal descending (VeLD) neurons, spinal inter-
neurons with axons that descend into the tail region by 43 h
(Kuwada et al., 1990; Hale et al., 2001). All VeLD interneu-
rons iontophoresed with smn MO (n   4) had axons that
traveled into the tail region and showed no other defects,
such as branching (unpublished data). This further indicates
that knockdown of Smn protein causes motoneuron-specific
defects. Taken together, these data show that Smn functions
cell autonomously in motoneurons and plays a critical and
specific role in motor axon outgrowth and pathfinding.
Discussion
Taking advantage of the relatively simple neuromuscular or-
ganization of the zebrafish embryo, we have shown that Smn
has an essential function in motor axon development. The
defects observed in motor axons upon knocking down Smn
are independent of cell death and are specific for motoneu-
rons. The data we present indicate that the earliest defects in
SMA are in the developing motor axons and suggest that
this defect in axon outgrowth and pathfinding may eventu-
ally lead to motoneuron death and SMA.
The motor axon defect in smn knockdown embryos
Embryos with decreased Smn levels show defects in motor
axon outgrowth and pathfinding during the first three days
of development. Defects were rarely seen in the proximal
axon extending from the spinal cord to the first intermediate
target, suggesting that initiation of axon outgrowth and
pathfinding along the common pathway are unaffected by
low Smn levels. Secondary motoneurons also displayed
branching and truncation defects that continued up to 3 d.
As primary and secondary motor axons fasciculate to form
nerves, we cannot be certain that the defects observed at 36–
72 h are defasciculation of the nerve or true branching of the
axons. As branching in single CaP axons is seen, this suggests
that true branching does occur. Although the motor axon
projections are aberrant, these axons still colocalized with
AChR, indicating that functional synapses had formed.
The motor axon branching and truncation defects were
initially discovered upon injection of 6 ng of smn MO into
zebrafish embryos. When a higher dose of MO, 9 ng, was
used, there was a significant increase in the amount of motor
axon branching and an apparent decrease in truncations.
Analysis of embryos with GFP-expressing motor nerves,
however, revealed that truncations were still occurring but
were followed by branching, thus obscuring the truncation
phenotype. These data indicate that the less Smn protein
translated within the neuron, the greater the likelihood that
the axon will branch. Ventral nerve truncations were consis-
tently occurring at the second intermediate target. It is be-
lieved that intermediate targets are important for growth
cones to proceed to their final targets (Tessier-Lavigne and
Goodman, 1996). It is possible that in the presence of low
Smn, growth cones stall at these locations, suggesting that
they still try to assimilate cues. At very low levels of Smn, the
growth cone may not even be responding to the intermedi-
ate target and branches indiscriminately.
Cell autonomy of Smn
Due to the distribution of SMN protein, it has been difficult
to conclusively determine whether the primary defect resides
in motoneurons or muscle. In smn MO–injected zebrafish
embryos, the motoneurons are defective, but muscle specifi-
cation, early patterning, and muscle development are nor-
mal, indicating that decreasing Smn is critical in motoneu-
rons. We specifically reduced Smn in single motoneurons
without affecting Smn levels in other neurons or muscle. Ex-
clusively decreasing Smn in motoneurons recapitulated the
motor axon defect seen when Smn was decreased through-
out the embryo, indicating that Smn functions cell autono-
mously. We cannot, however, rule out the possibility that
Smn also functions in muscle to affect motor axons.
Smn and motor axons
Recent mouse and human studies suggest that motor axons
may be affected before motoneuron loss. Mice exhibiting
neuronal depletion of SMN (Smn
F7/Smn
D7, NSE-Cre
 ) ex-
hibited a dramatic decrease in motor axons but only a mod-
est decrease in motoneuron cell bodies at postnatal day 15
(Cifuentes-Diaz et al., 2002). Due to the severe reduction in
full-length SMN and the relatively late developmental tim-
ing of this reduction, however, it is difficult to determine the
disease relevance of these defects. Severe SMA mice (Smn
 / 
with one to two copies of SMN2; Hsieh-Li et al., 2000; Mo-
nani et al., 2000) show moderate motoneuron cell body loss,
whereas mild SMA mice (A2G missense) show no motoneu-
ron cell body loss several days after birth; mild SMA mice
do, however, exhibit a mild reduction in both motoneuron
cell bodies and motor axon roots at 3.5 mo (Monani et al.,
2003). Motor unit number estimation (MUNE) studies in
humans show that presymptomatic individuals exhibit high
motoneuron counts that dramatically decrease with onset of
the disease (Bromberg and Swoboda, 2002). These results
indicate that motoneuron cell body loss is a late feature of
the disease. Our data are consistent with these findings and
support the idea that axons are affected before cell death.
SMN has also been shown to localize in developing moto-
neurons. Rat SMN colocalizes with cytoskeletal elements in
the spinal motor axons during nervous system maturation
(Pagliardini et al., 2000). In primary motoneuron cultures
from E14 mice embryos, SMN is enriched in branch points
and growth cones (Jablonka et al., 2001). SMN has also
been found in growth cones of P19 neurons (Fan and Si-
mard, 2002). Interestingly, SMN interacting protein 1
(SIP1), a protein important in spliceosomal snRNP biogene-
sis (Fischer et al., 1997), does not coenrich in axon branch
points, indicating the possibility of a unique SMN complex
and function at these locations (Jablonka et al., 2001).
Taken together with our findings of abnormal motor axon
branching when Smn is depleted, the data suggest that SmnT
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plays an important function in motor axon development
and maintenance.
Although a mechanism by which SMN functions in mo-
toneuron development remains unclear, recent data do give
clues. SMN has been shown to interact with profilin
(Giesemann et al., 1999), a protein involved in actin poly-
merization and growth cone motility (Gutsche-Perelroizen
et al., 1999; Wills et al., 1999; Kim et al., 2001), processes
important for axon outgrowth. Data have also implicated
an interaction between SMN and motoneuron-enriched
RNA processing molecules, hn-RNP-Q and hn-RNP-R
(Rossoll et al., 2002). These proteins play a role in RNA
transport, editing, and translation. RNA transport into the
axon followed by localized protein translation has been
shown to be important for growth cones to proceed past in-
termediate targets (Brittis et al., 2002). It is possible that
SMN in axons and growth cones may be associated with
RNP complex assembly associated with transport and/or
translation of mRNA. Recent experiments have shown that
SMN localizes with cytoskeletal filaments and is actively
transported down axons (Zhang et al., 2003), further indi-
cating that SMN may be involved in transport and the re-
sulting translation of important axon guidance cues. It is
possible that if SMN is reduced, motor axons cannot re-
spond to cues at intermediate targets by turning on local
translation, resulting in axon defects. Our finding that
GFP-expressing motor nerves in smn MO–injected em-
bryos are truncated at the second intermediate target is con-
sistent with this idea. The validity of this model, however,
will depend on elucidating a direct relationship between
Smn and localized protein translation machinery in motor
axon growth cones.
Materials and methods
Fish maintenance
Adult zebrafish and embryos were maintained as previously described
(Westerfield, 1995), allowed to develop at  28.5 C, and staged by hours
or days after fertilization (Kimmel et al., 1995). All fish used in this study
were on the *AB background unless otherwise specified.
Nomenclature
Consistent with guidelines for different species, the mouse, human, or rat
protein is SMN and the gene is SMN (human) or Smn (mouse). In fish, the
protein is Smn, and the gene is smn (http://zfin.org/zf_info/nomen.html).
Physical mapping and southern blot analysis
Zebrafish  smn primers (5 -GTGATGATTCTGACATTTGG-3  and 5 -
CCATCCTCACCTTTCAAAGC-3 ) were used to map the gene on the LN54
radiation hybrid panel (Hukriede et al., 1999). smn maps to linkage group
5, 3.25 cM from marker fb39c12. Southern blots were performed as previ-
ously described (Monani et al., 2000). The smn probe was generated
by PCR with the following primer sequences: 5 -GTGATGATTCTGA-
CATTTGG-3  and 5 -GTCTTCAGAGCATCTTCATCC-3 . The zebrafish
islet2 gene was used as a control.
Whole-mount in situ hybridization
Zebrafish  smn cDNA clone (GenBank/EMBL/DDBJ accession nos.
Y17256, AA494875, AA494767, and AF083557) was used to make sense
and antisense digoxigenin-labeled riboprobes of 1016 bp (Bertrandy et al.,
1999). The sense (Sp6) and antisense (T7) smn riboprobes were synthe-
sized from plasmid linearized with XhoI and HindIII, respectively. Islet2
and MyoD riboprobes were synthesized as previously described (Appel et
al., 1995; Weinberg et al., 1996). Whole-mount in situ hybridization pro-
tocol (1277073; Roche) was performed as previously described (Thisse et
al., 1993).
Antisense MO and synthetic mRNA injections
An antisense MO was designed against the 5  start sequence of the smn
gene (Gene Tools, Inc.); 5 -CGACATCTTCTGCACCATTGGC-3 . An addi-
tional nonoverlapping MO was also designed  20 bp upstream of the
original MO (designated 5  UTR MO); 5 -TTTAAATATTTCCCAAGTC-
CAACGT-3 . Two- to four-cell *AB, gata2–GFP (Meng et al., 1997), or
islet1–GFP (Higashijima et al., 2000) embryos were injected with  6 or 9
ng of MO in Danieau’s solution with phenol red dye according to protocol
(Nasevicius and Ekker, 2000). A standard control (Gene Tools, Inc.) MO
(5 -CCTCTTACCTCAGTTACAATTTATA-3 ) was used at 6 or 9 ng for con-
trol injections. Synthetic capped human SMN mRNA was produced using
mMESSAGE mMACHINE kit (Ambion) according to the manufacturer’s in-
structions. mRNA was produced from previously described plasmids (Le et
al., 2000) linearized with Xho1. Approximately 300–500 pg of mRNA was
coinjected with 9 ng of smn MO.
Immunohistochemistry
Immunohistochemistry and imaging were performed essentially as previ-
ously described (Beattie et al., 2000). The following mAbs were used: znp1
(1:100; Melancon et al., 1997), anti–acetylated tubulin (1:250; T-6793;
Sigma-Aldrich), anti–slow twitch myosin F59 (1:10; Crow and Stockdale,
1986; Devoto et al., 1996), anti–fast twitch myosin F310 (1:10; Crow and
Stockdale, 1986; Zeller et al., 2002), 3A10 (1:10; Hatta, 1992), and anti–
neurolin zn-5 (1:75; Fashena and Westerfield, 1999). FITC (IgG2A) and
TRITC (IgG1) isotype-specific conjugate secondary Abs (1080–02 and
1070–03, respectively; Southern Biotechnology Associates, Inc.) were
used for fluorescent detection of znp-1 (IgG2A) and F59/F310 (IgG1)
mAbs. Cross-sectional analysis was performed by embedding embryos in
1.5% agar/5% sucrose and sectioning on a crytostat at 16  m. All immu-
nofluorescent images were analyzed using a confocal microscope and
photographed using digital imagery (Nikon Optiphot 2; Bio-Rad Laborato-
ries, Inc. MRC 1024) unless otherwise specified.
Western blot analysis
MO-injected embryos were manually dechorionated and deyolked in a
slurry of physiologic Ringers (Westerfield, 1995), Ringers ice chips, and
protease inhibitors (Complete Mini; 1836170; Roche). Deyolked em-
bryo samples were prepared and Western blots were performed as previ-
ously described (Monani et al., 2003). Smn (1:1,000; MANSMA7 or
MANSMA21; Young et al., 2000b), anti–synaptic vesicle (SV2) protein
(1:200; Buckley and Kelly, 1985), and anti–Hu 16A11 (1:500; A-21271;
Molecular Probes; Marusich et al., 1994) mAb were visualized using the
ECL Detection Kit (RPN 2109; Amersham Biosciences). Quantification of
bands was performed using a densitometer (Shimadzu, Inc.).
Visualization of GFP transgenic zebrafish
Live gata2–GFP MO-injected transgenic zebrafish (Meng et al., 1997) were
anesthetized in tricaine (A-5040; Sigma-Aldrich) at 36, 52, and 74 h and
mounted on a glass coverslip. Individual motor nerves were visualized
and imaged using a Photometrics SPOT camera. Images were compiled
and edited using Adobe Photoshop
® software. MO-injected islet1–GFP
embryos (Higashijima et al., 2000) were fixed at 72 h in 4% paraformalde-
hyde for 2 h at room temperature.
TUNEL assay
TUNEL assay was performed according to the manufacturer’s protocol on
staged embryos (Cole and Ross, 2001). Digoxigenin-labeled dUTP was
used to label fragmenting DNA ends (Terminal Transferase Assay; 220582;
Roche), and then embryos were sectioned on a crytostat at 16  m.
Detection of neuromuscular junctions
MO-injected embryos were staged and fixed in 4% paraformaldehyde for
2 h at room temperature and water soaked for 3–6 h. After collagenase
(C-9891; Sigma-Aldrich) treatment, embryos were then incubated in
Alexa
®594-conjugated   -bungarotoxin (10  g/ml; B13423; Molecular
Probes) for 30 min, essentially as previously described (Ono et al., 2001).
Embryos were then Ab stained using znp-1 and a FITC-conjugated second-
ary Ab.
Single cell knockdown of smn
Glass capillary microelectrodes were backfilled with a solution containing
2.5% rhodamine dextran (3,000 MW; Molecular Probes) and smn or con-
trol MO. 19.5–20.5-h embryos were anesthetized in tricaine and mounted
in agar on a microslide as previously described (Eisen et al., 1989; Beattie
et al., 2000). Individual CaP motoneurons or VeLD interneurons were im-T
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paled electrically by oscillating the electrode tip as previously described
(Eisen et al., 1989). Solution was added to the cell by iontophoresis. Im-
ages were taken with a Photometrics SPOT camera and compiled and ed-
ited in Adobe Photoshop
®.
Online supplemental material
The supplemental material is available at http://www.jcb.org/cgi/content/
full/jcb.200303168/DC1. Fig. S1 diagrams primary and secondary motor
axon pathfinding in the developing zebrafish. Fig. S2 shows the expression
pattern of smn during the development of zebrafish. Fig. S3 shows that an
additional 5  UTR smn MO results in similar motor axon defects. Table SI
shows the percentage of sides with motor axon/nerve defects using addi-
tional 5  UTR smn MO.
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